308 related articles for article (PubMed ID: 27253087)
1. Prophylaxis in von Willebrand Disease: Coming of Age?
Saccullo G; Makris M
Semin Thromb Hemost; 2016 Jul; 42(5):498-506. PubMed ID: 27253087
[TBL] [Abstract][Full Text] [Related]
2. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
3. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network.
Abshire T; Cox-Gill J; Kempton CL; Leebeek FW; Carcao M; Kouides P; Donfield S; Berntorp E
J Thromb Haemost; 2015 Sep; 13(9):1585-9. PubMed ID: 25930155
[TBL] [Abstract][Full Text] [Related]
5. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology, diagnosis, and management of von Willebrand disease in India.
Ghosh K; Shetty S
Semin Thromb Hemost; 2011 Jul; 37(5):595-601. PubMed ID: 22102205
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis and management of von Willebrand disease].
Higasa S; Tokugawa T; Sawada A
Rinsho Ketsueki; 2018; 59(10):2222-2232. PubMed ID: 30305529
[TBL] [Abstract][Full Text] [Related]
8. Haemostatic management of intraoral bleeding in patients with von Willebrand disease.
Morimoto Y; Yoshioka A; Sugimoto M; Imai Y; Kirita T
Oral Dis; 2005 Jul; 11(4):243-8. PubMed ID: 15984956
[TBL] [Abstract][Full Text] [Related]
9. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
Federici AB
Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
[TBL] [Abstract][Full Text] [Related]
10. Monitoring Therapy during Treatment of von Willebrand Disease.
Favaloro EJ; Pasalic L; Curnow J
Semin Thromb Hemost; 2017 Apr; 43(3):338-354. PubMed ID: 27472426
[TBL] [Abstract][Full Text] [Related]
11. Treatment of von Willebrand disease.
Rodeghiero F; Castaman G
Semin Hematol; 2005 Jan; 42(1):29-35. PubMed ID: 15662613
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis of bleeding episodes in patients with von Willebrand's disease.
Federici AB
Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s26-32. PubMed ID: 19105507
[TBL] [Abstract][Full Text] [Related]
13. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
14. Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes.
Chandrakumaran P; Hews-Girard J; Poon MC
Haemophilia; 2023 Jul; 29(4):1095-1103. PubMed ID: 37257847
[TBL] [Abstract][Full Text] [Related]
15. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.
Franchini M; Mannucci PM
Expert Rev Hematol; 2016 Sep; 9(9):825-30. PubMed ID: 27427955
[TBL] [Abstract][Full Text] [Related]
16. Von Willebrand Disease and Pregnancy: A Review of Evidence and Expert Opinion.
Reynen E; James P
Semin Thromb Hemost; 2016 Oct; 42(7):717-723. PubMed ID: 27648611
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive evaluation of haemostatic function in von Willebrand disease patients using a microchip-based flow chamber system.
Ogiwara K; Nogami K; Hosokawa K; Ohnishi T; Matsumoto T; Shima M
Haemophilia; 2015 Jan; 21(1):71-80. PubMed ID: 25545301
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis in von Willebrand disease.
Franchini M; Targher G; Lippi G
Ann Hematol; 2007 Oct; 86(10):699-704. PubMed ID: 17634944
[TBL] [Abstract][Full Text] [Related]
19. New treatment approaches to von Willebrand disease.
Lavin M; O'Donnell JS
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):683-689. PubMed ID: 27913547
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3.
Berntorp E
Semin Thromb Hemost; 2006 Sep; 32(6):621-5. PubMed ID: 16977572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]